Delayed Sunday, November 15 edition. Summit says the FDA issued a complete response letter for ivonescimab plus chemotherapy in previously treated EGFR-mutated lung cancer. Novo Nordisk detailed two lower doses of CagriSema in obesity, and Pfizer arranged development funding of up to $1.5 billion from Blackstone-managed funds for its investigational monthly GLP-1 berobenatide. We also cover FDA approvals for Gazyva (obinutuzumab) in adults with primary membranous nephropathy at risk of progression, and Imfinzi (durvalumab) with Padcev (enfortumab vedotin) in bladder cancer, new CHMP opinions, three hereditary angioedema updates, and the week ahead at ObesityWeek and CTAD.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →